Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform

Over the last four years, the Lipid-Calcium-Phosphate (LCP) nanoparticle platform has shown success in a wide range of treatment strategies, recently including theranostics. The high specific drug loading of radiometals into LCP, coupled with its ability to efficiently encapsulate many types of cytotoxic agents, allows a broad range of theranostic applications, many of which are yet unexplored. In addition to providing an overview of current medical imaging modalities, this review highlights the current theranostic applications for LCP using SPECT and PET, and discusses potential future uses of the platform by comparing it with both systemically and locally delivered clinical radiotherapy options as well as introducing its applications as an MRI contrast agent. Strengths and weaknesses of LCP and of nanoparticles in general are discussed, as well as caveats regarding the use of fluorescence to determine the accumulation or biodistribution of a probe.

[1]  M J Welch,et al.  Efficient production of high specific activity 64Cu using a biomedical cyclotron. , 1997, Nuclear medicine and biology.

[2]  Yuan Zhang,et al.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[3]  L. Zakharov,et al.  Kinetic Inertness and Electrochemical Behavior of Copper(II) Tetraazamacrocyclic Complexes: Possible Implications for in Vivo Stability , 2005 .

[4]  H. Jacobsson,et al.  99mTc-exametazime as a breast tumor-seeking agent: comparison with 99mTc-sestamibi. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  G. Hellawell,et al.  High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. , 2012, The British journal of radiology.

[6]  Yu-cheng Tseng,et al.  Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Antonio J. Grillo-López,et al.  Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma , 2002, Expert review of anticancer therapy.

[8]  Sang-Woo Lee,et al.  Targeting of hepatocellular carcinoma with glypican‐3‐targeting peptide ligand , 2011, Journal of peptide science : an official publication of the European Peptide Society.

[9]  Yang Liu,et al.  Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. , 2014, Biomaterials.

[10]  D. Maloney,et al.  Rituximab resistance. , 2011, Best practice & research. Clinical haematology.

[11]  A. Maitra.  Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy , 2005, Expert review of molecular diagnostics.

[12]  Suleman Surti,et al.  Benefit of Time-of-Flight in PET: Experimental and Clinical Results , 2008, Journal of Nuclear Medicine.

[13]  Haisheng Peng,et al.  A new peptide ligand for colon cancer targeted delivery of micelles , 2016, Drug delivery.

[14]  G. Cheon,et al.  Revival of TE2A; a better chelate for Cu(II) ions than TETA? , 2010, Chemical communications.

[15]  F. Blankenberg,et al.  99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  M. Lubberink,et al.  Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma , 2012, Theranostics.

[17]  Kara D. Weatherman,et al.  Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine , 2011 .

[18]  F. Liu,et al.  Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  Biodistribution Studies of Nanoparticles Using Fluorescence Imaging: A Qualitative or Quantitative Method? , 2012, Pharmaceutical Research.

[20]  M. Khalil,et al.  Molecular SPECT Imaging: An Overview , 2011, International journal of molecular imaging.

[21]  Yu-cheng Tseng,et al.  Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. , 2014, Biomaterials.

[22]  G. Rubini,et al.  Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study , 2015, BioMed research international.

[23]  Hyundong Yoo,et al.  Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery , 2014, Archives of Pharmacal Research.

[24]  D. Kerr,et al.  Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.

[25]  R Nath,et al.  Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. , 1999, Medical physics.

[26]  R. Heumann,et al.  Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. , 2006, Biomaterials.

[27]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[28]  Pat Zanzonico,et al.  Basic Sciences of Nuclear Medicine. , 2011, Medical physics.

[29]  Yuhua Wang,et al.  Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[30]  Yuan Zhang,et al.  Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[31]  Jung Young Kim,et al.  Synthesis and Evaluation of New Generation Cross-Bridged Bifunctional Chelator for (64)Cu Radiotracers. , 2015, Inorganic chemistry.

[32]  G. Bydder,et al.  INTRAVENOUS CHELATED GADOLINIUM AS A CONTRAST AGENT IN NMR IMAGING OF CEREBRAL TUMOURS , 1984, The Lancet.

[33]  W. Cavanagh,et al.  Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point , 2007 .

[34]  K. Ulbrich,et al.  Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. , 1996, Journal of drug targeting.

[35]  Wei-Hua Chen,et al.  Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. , 2015, Cancer letters.

[36]  Zheyu Shen,et al.  Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. , 2016, Materials science & engineering. C, Materials for biological applications.

[37]  A. D. Di Pasqua,et al.  Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer , 2013, The Journal of Nuclear Medicine.

[38]  P. Meyer,et al.  Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. , 2015, Molecular pharmaceutics.

[39]  Shraddha S. Nigavekar,et al.  Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy. , 2008, Nanomedicine : nanotechnology, biology, and medicine.

[40]  E. Roberts,et al.  Liver as a key organ in the supply, storage, and excretion of copper. , 2008, The American journal of clinical nutrition.

[41]  Kowalsky Rj,et al.  Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 2nd edition , 2006 .

[42]  J. Hogg.  Magnetic resonance imaging. , 1994, Journal of the Royal Naval Medical Service.

[43]  Leaf Huang,et al.  Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[44]  Tushar C. Barot,et al.  Yttrium-90 Microsphere-selective Internal Radiation Therapy With Chemotherapy (Chemo-SIRT) for Colorectal Cancer Liver Metastases: An In Vivo Double-Arm–Controlled Phase II Trial , 2013, American journal of clinical oncology.

[45]  R R Edelman,et al.  Magnetic resonance imaging (1). , 1993, The New England journal of medicine.

[46]  P. Rehm,et al.  Indium-111 Capromab Pendetide (ProstaScint®) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma , 2015, World journal of nuclear medicine.

[47]  L. Kvols,et al.  Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors: The First US Phase 2 Experience , 2014, Pancreas.

[48]  Martin G Pomper,et al.  Clinical applications of Gallium-68. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[49]  J. Filmus,et al.  Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma , 2013, The FEBS journal.

[50]  William Y. Kim,et al.  Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[52]  Christopher B. Howard,et al.  Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells. , 2015, Journal of materials chemistry. B.

[53]  Z. Cai,et al.  Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. , 2005, Cancer biotherapy & radiopharmaceuticals.

[54]  C. Vanhove,et al.  Review of SPECT collimator selection, optimization, and fabrication for clinical and preclinical imaging. , 2015, Medical physics.

[55]  M. Bartholomä.  Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography , 2012 .

[56]  Yuhua Wang,et al.  Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. , 2013, ACS nano.

[57]  Timothy J. Hoffman,et al.  In Vivo Evaluation and Small-Animal PET/CT of a Prostate Cancer Mouse Model Using 64Cu Bombesin Analogs: Side-by-Side Comparison of the CB-TE2A and DOTA Chelation Systems , 2007, Journal of Nuclear Medicine.

[58]  Håkan Wallin,et al.  Kupffer cells are central in the removal of nanoparticles from the organism , 2007, Particle and Fibre Toxicology.

[59]  Yuhua Wang,et al.  Nanoparticle-Delivered Transforming Growth Factor-β siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment , 2014, ACS nano.

[60]  K. M. Au,et al.  Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. , 2016, Biomaterials.

[61]  P. Dittrich,et al.  Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[62]  William Cavanagh,et al.  A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. , 2007, Brachytherapy.

[63]  Yuan Zhang,et al.  Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. , 2013, Biomaterials.

[64]  Jin Xie,et al.  Nanoparticle-based theranostic agents. , 2010, Advanced drug delivery reviews.

[65]  Jung Young Kim,et al.  New bifunctional chelator for 64Cu-immuno-positron emission tomography. , 2013, Bioconjugate chemistry.

[66]  Feng Liu,et al.  A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. , 2013, ACS nano.

[67]  J. Gitlin,et al.  Ceruloplasmin metabolism and function. , 2002, Annual review of nutrition.

[68]  C. Anderson,et al.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. , 2010, Chemical reviews.

[69]  M. Lubberink,et al.  Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment , 2013, The Journal of Nuclear Medicine.

[70]  Leaf Huang,et al.  A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[71]  Yuhua Wang,et al.  Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[72]  William Y. Kim,et al.  Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. , 2013, Biomaterials.

[73]  R. Qin,et al.  Effects of down-regulation of integrin-β1 expression on migration and hepatic metastasis of human colon carcinoma , 2010, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[74]  Yu-cheng Tseng,et al.  How does the cell overcome LCP nanoparticle-induced calcium toxicity? , 2013, Molecular pharmaceutics.

[75]  Éva Tóth,et al.  The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging , 2013 .

[76]  H. Kulkarni,et al.  Rituximab and Cytokine Release Syndrome , 2012, Case Reports in Oncology.

[77]  V. Gebski,et al.  Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study , 2014, BMC Cancer.

[78]  V. Masilamani,et al.  Cancer diagnosis by autofluorescence of blood components , 2004 .

[79]  Haeshin Lee,et al.  Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[80]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  C. Anderson,et al.  Copper chelation chemistry and its role in copper radiopharmaceuticals. , 2007, Current pharmaceutical design.

[82]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[83]  F. Liu,et al.  Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. , 2012, Molecular pharmaceutics.